• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

In­cyte adds first Opzelu­ra brand TV com­mer­cial, and a fa­mous voice, to its vi­tili­go ef­forts

3 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Pfiz­er, Vi­iV pull up to cham­pagne car­pet at Os­cars; Bris­tol My­ers de­buts orig­i­nal film

3 years ago
Pharma
Marketing

No­var­tis looks to of­fload even more of its eye prod­ucts — re­port

3 years ago
Deals

Fur­ther shuf­fling at Leo Phar­ma as der­ma­tol­ogy drug­mak­er splits R&D

3 years ago
People
R&D

Servi­er says its next IDH in­hibitor has passed PhI­II, but no reg­u­la­to­ry time­line yet

3 years ago
R&D

Synaf­fix ex­pands ADC deal from 2022 with Macro­Gen­ics

3 years ago
Deals
R&D

Phar­ma ad­ver­tis­ers’ cov­et­ed 50+ au­di­ence flocks to stream­ing TV, Roku analy­sis says

3 years ago
Pharma
Marketing

CRISPR hires William Blair an­a­lyst as new fi­nance chief; Tiny EU biotech rais­es $20M+

3 years ago
News Briefing

Bris­tol My­ers pass­es on two Ex­sci­en­tia on­col­o­gy can­di­dates, but biotech to move them in­to clin­ic next year

3 years ago
Deals
R&D

Ex­er­cise in a pill? That's the fo­cus of Cam­bri­an's new pipeline com­pa­ny

3 years ago
Financing
R&D

Cell­tri­on teams up with an­oth­er Ko­re­an bio­phar­ma in an­ti­body dis­cov­ery deal

3 years ago
Deals
Discovery

Amy­lyx's ALS drug sales beat Wall Street ex­pec­ta­tions in first full quar­ter

3 years ago
Pharma

Eli Lil­ly, UCB and oth­ers Switch in­to gear with $52M for new RNA biotech

3 years ago
Financing
Startups

No­vo-backed start­up touts a PhII win for atri­al fib­ril­la­tion pro­gram

3 years ago
R&D

VA to cov­er Ei­sai's new Alzheimer's drug af­ter de­clin­ing to cov­er Aduhelm

3 years ago
Pharma

Sun Phar­ma, Taro Phar­ma­ceu­ti­cal reach $75M set­tle­ment agree­ment in al­leged price fix­ing scheme

3 years ago
R&D
Law

Re­searchers ques­tion val­ue of Medicare Part D cov­er­age for obe­si­ty drugs

3 years ago
Pharma

PhRMA-backed al­liance says it wants to 'mod­ern­ize' the 340B pro­gram. Crit­ics say the changes will on­ly lim­it ac­cess

3 years ago
Pharma

GSK chief Em­ma Walm­s­ley sees pay raise amid 'land­mark' year

3 years ago
People
Pharma

Pfiz­er CEO points to IRA as a fac­tor that made Seagen an at­trac­tive tar­get

3 years ago
Pharma
Law

Al­con takes a new look at oph­thalmic phar­ma space and mar­ket­ing, post No­var­tis spin­out and raft of ac­qui­si­tions

3 years ago
Marketing

Mer­ck asks EMA to reeval­u­ate re­ject­ed Covid-19 an­tivi­ral

3 years ago
FDA+
Coronavirus

Im­munother­a­py biotech un­stealths with $13M; An­ti-in­fec­tion can­di­date for CF pass­es safe­ty tri­al

3 years ago
News Briefing

For­mer long­time an­a­lyst Ja­mi Ru­bin re­signs from EQRx's CFO role

3 years ago
People
First page Previous page 362363364365366367368 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times